Drug Profile
RG 7667
Alternative Names: MCMV-3068A; MCMV-5322A; RG-7667; RO-6855848; RO-6855849Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 16 Oct 2014 Discontinued - Phase-II for Cytomegalovirus infections (Prevention) in USA, UK, Belgium, France, Germany, Norway, Spain, Sweden (IV)
- 15 Sep 2014 Genentech completes a phase II trial in Cytomegalovirus infections in USA, United Kingdom, Belgium, Germany, France, Norway, Spain and Sweden (EudraCT2012-002245-37)
- 01 Feb 2013 Genentech completes a phase I trial in Healthy volunteers in USA (NCT01496755)